Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20914358 | 0.89 | LMNA (0.37) | LMNAMAPTMEN1KMT2ASYK | |
| SCHEMBL20913982 | 0.81 | MAT2A (0.34) | MEN1KMT2A | |
| SCHEMBL20913941 | 0.78 | LMNA (0.37) | LMNAMAPTSYK | |
| SCHEMBL20914269 | 0.76 | MAT2A (0.33) | LMNA | |
| SCHEMBL20914031 | 0.76 | APLNR (0.35) | LMNAMAPTMEN1KMT2A | |
| SCHEMBL20914298 | 0.76 | APLNR (0.39) | MEN1KMT2A | |
| SCHEMBL20819060 | 0.75 | APLNR (0.35) | MEN1KMT2A | |
| SCHEMBL20837243 | 0.75 | KDM4E (0.33) | LMNAMEN1KMT2A | |
| SCHEMBL20914148 | 0.74 | F2RL3 (0.32) | LMNAMEN1KMT2A | |
| SCHEMBL20914018 | 0.73 | MAT2A (0.34) | LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | LMNA 4242/4885MAPT 214/4885MEN1 2785/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | LMNA 4242/4885MAPT 214/4885MEN1 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.